Philadelphia Phillies outfielder Johan Rojas has been handed an 80-game suspension without pay after testing positive for Boldenone, a performance-enhancing drug, Major League Baseball announced on March 16, 2026. The news brings a sudden and significant shift to the Phillies’ roster plans just weeks before Opening Day, and it leaves Rojas ineligible for the postseason regardless of how the suspension unfolds.
The failed drug test first surfaced in early March, as Rojas was abruptly removed from the Dominican Republic’s roster for the World Baseball Classic. While the suspension was still under appeal, the 25-year-old outfielder remained active in Phillies spring training, taking part in Grapefruit League games and practicing with teammates at BayCare Ballpark. On March 4, when asked by reporters about the situation, Rojas declined to comment due to the ongoing appeal process.
Ultimately, the appeal was denied by independent arbitrator Martin F. Scheinman, and the discipline was upheld. According to MLB, Rojas’ suspension will begin with the start of the 2026 regular season, sidelining him for approximately half the year. Barring rainouts or postponements, he will be eligible to return on June 25, 2026, after serving 92 days of the 187-day season. During this period, Rojas will forfeit $395,305 in salary, a significant portion of his $803,500 major league contract.
The Phillies, in a statement released Monday, expressed their stance on the matter: "The Phillies fully support Major League Baseball’s Joint Prevention and Treatment Program and are disappointed to hear today’s news of Johan’s violation." Their disappointment is palpable, not just for the infraction itself but for the ripple effects on the team’s depth and defensive plans.
Rojas’ journey with the Phillies began when he debuted in the majors in 2023. Known for his elite defense and base-stealing prowess, he nonetheless struggled to find consistent success at the plate. In the 2025 season, Rojas appeared in 71 games, batting .224 with a .280 on-base percentage and a .289 slugging percentage, tallying one home run, 18 RBIs, and 12 stolen bases. His offensive challenges led to a demotion to Triple-A Lehigh Valley on August 1, 2025, where he fared better, hitting .279 over 147 at-bats. In spring training this year, Rojas posted a .167 average across 10 games, further dimming his chances of breaking camp with the big-league club.
Despite those numbers, Rojas remained a valuable depth option for the Phillies’ outfield. The team’s plans for 2026 included giving top prospect Justin Crawford a shot in center field, with Brandon Marsh likely to platoon in left field alongside Otto Kemp. Rojas, with his glove and speed, would have been the first right-handed option in center if Crawford struggled or suffered an injury. Now, that safety net is gone for at least the first half of the season—and the postseason is off the table entirely for Rojas.
Beyond the immediate impact on the Phillies, Rojas’ suspension is part of a broader trend in Major League Baseball this year. He is the sixth player to be disciplined for a drug violation in 2026 and the third under the major league agreement. Atlanta Braves designated hitter Jurickson Profar was suspended for 162 games earlier this month after a second PED offense, while free agent and former Phillies outfielder Max Kepler received an 80-game ban in January for testing positive for Epitrenbolone. Phillies reliever José Alvarado was also suspended for 80 games last season, underscoring a troubling pattern of PED violations in the league and within the organization.
“The Phillies fully support Major League Baseball’s Joint Prevention and Treatment Program and are disappointed to hear today’s news of Johan’s violation,” the club reiterated in its official statement, standing firmly behind the league’s efforts to maintain a level playing field. The suspension has also forced the Phillies to reconsider their outfield depth chart as Opening Day approaches. With Rojas out, Marsh is the most likely candidate to shift to center if Crawford falters, but beyond him, options are thin. Pedro León, who has 205 minor league games in center but just seven in the majors, was optioned to Triple-A Lehigh Valley. Non-roster invitees like Bryan De La Cruz and prospect Dante Nori (expected to start the season at Double-A Reading) offer limited experience in center field, while utility man Dylan Moore, not on the 40-man roster, has only 17 career games in center.
Rojas’ absence is particularly notable because of his defensive value. Over 250 major league games, he has posted a .252 average with six home runs, 73 RBIs, and 51 stolen bases, but his glove has consistently rated above average. Since the start of 2024, however, his offensive production has lagged, with a .237/.279/.312 line translating to a 64 wRC+—36% below league average. The Phillies’ acquisition of Harrison Bader at last year’s trade deadline and the promotion of Crawford reflect the organization’s shifting priorities, but Rojas’ suspension removes a key speed-and-defense fallback from the equation.
With Opening Day set for March 26 at Citizens Bank Park against the Texas Rangers, the Phillies’ front office may look to add further outfield depth via waivers or late-spring free agency. The current market for center fielders is thin, but roster moves around the league could present new opportunities in the coming weeks. For now, the Phillies must navigate the early part of the season without one of their most dynamic defenders and with a bench picture that remains in flux. As for Rojas, the suspension is a major setback at a critical juncture in his career—his role with the Phillies, and perhaps his future in Major League Baseball, suddenly uncertain.
Johan Rojas’ story serves as a stark reminder of the consequences of violating MLB’s drug policy and the far-reaching impact such decisions can have on a player, a clubhouse, and a team’s championship aspirations. The Phillies, disappointed but resolute, will regroup and adapt as the 2026 season dawns, their quest for October glory now unfolding without one of their most electrifying outfielders.